Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 333

1.

Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.

Gottwein JM, Scheel TK, Jensen TB, Ghanem L, Bukh J.

Gastroenterology. 2011 Sep;141(3):1067-79. doi: 10.1053/j.gastro.2011.06.004. Epub 2011 Jun 12.

PMID:
21699793
2.

Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.

Li YP, Ramirez S, Humes D, Jensen SB, Gottwein JM, Bukh J.

Gastroenterology. 2014 Mar;146(3):812-821.e4. doi: 10.1053/j.gastro.2013.11.009. Epub 2013 Nov 18.

PMID:
24262279
3.

Adapted J6/JFH1-based Hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor.

Gottwein JM, Jensen SB, Serre SB, Ghanem L, Scheel TK, Jensen TB, Krarup H, Uzcategui N, Mikkelsen LS, Bukh J.

Antimicrob Agents Chemother. 2013 Dec;57(12):6034-49. doi: 10.1128/AAC.01176-13. Epub 2013 Sep 23.

4.

Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.

Gottwein JM, Jensen SB, Li YP, Ghanem L, Scheel TK, Serre SB, Mikkelsen L, Bukh J.

Antimicrob Agents Chemother. 2013 Mar;57(3):1291-303. doi: 10.1128/AAC.02164-12. Epub 2012 Dec 28.

5.

Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses.

Gottwein JM, Scheel TK, Hoegh AM, Lademann JB, Eugen-Olsen J, Lisby G, Bukh J.

Gastroenterology. 2007 Nov;133(5):1614-26. Epub 2007 Aug 3.

PMID:
17983807
6.

Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.

López-Labrador FX, Moya A, Gonzàlez-Candelas F.

Antivir Ther. 2008;13(4):481-94.

PMID:
18672527
7.

Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors.

Ramirez S, Li YP, Jensen SB, Pedersen J, Gottwein JM, Bukh J.

Hepatology. 2014 Feb;59(2):395-407. doi: 10.1002/hep.26660. Epub 2013 Dec 13.

PMID:
23913364
8.
9.

Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins.

Massariol MJ, Zhao S, Marquis M, Thibeault D, White PW.

Biochem Biophys Res Commun. 2010 Jan 1;391(1):692-7. doi: 10.1016/j.bbrc.2009.11.122. Epub 2009 Nov 26.

PMID:
19944069
10.

Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization.

Scheel TK, Gottwein JM, Jensen TB, Prentoe JC, Hoegh AM, Alter HJ, Eugen-Olsen J, Bukh J.

Proc Natl Acad Sci U S A. 2008 Jan 22;105(3):997-1002. doi: 10.1073/pnas.0711044105. Epub 2008 Jan 14.

12.

Development and application of hepatitis C reporter viruses with genotype 1 to 7 core-nonstructural protein 2 (NS2) expressing fluorescent proteins or luciferase in modified JFH1 NS5A.

Gottwein JM, Jensen TB, Mathiesen CK, Meuleman P, Serre SB, Lademann JB, Ghanem L, Scheel TK, Leroux-Roels G, Bukh J.

J Virol. 2011 Sep;85(17):8913-28. doi: 10.1128/JVI.00049-11. Epub 2011 Jun 22.

13.

The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors.

Romano KP, Ali A, Aydin C, Soumana D, Ozen A, Deveau LM, Silver C, Cao H, Newton A, Petropoulos CJ, Huang W, Schiffer CA.

PLoS Pathog. 2012;8(7):e1002832. doi: 10.1371/journal.ppat.1002832. Epub 2012 Jul 26.

14.

Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection.

Deutsch M, Papatheodoridis GV.

Curr Opin Investig Drugs. 2010 Aug;11(8):951-63.

PMID:
20721837
15.

Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations.

Scheel TK, Gottwein JM, Carlsen TH, Li YP, Jensen TB, Spengler U, Weis N, Bukh J.

J Virol. 2011 Mar;85(6):2891-906. doi: 10.1128/JVI.01605-10. Epub 2010 Dec 22.

16.

Development of robust in vitro serine protease assay based on recombinant Pakistani HCV NS3-4A protease.

Fatima K, Tahir M, Qadri I.

Virus Res. 2011 Sep;160(1-2):230-7. doi: 10.1016/j.virusres.2011.06.020. Epub 2011 Jul 2.

PMID:
21756947
17.

Hepatitis C virus resistance to protease inhibitors.

Halfon P, Locarnini S.

J Hepatol. 2011 Jul;55(1):192-206. doi: 10.1016/j.jhep.2011.01.011. Epub 2011 Feb 1. Review.

18.

Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection.

Jensen TB, Gottwein JM, Scheel TK, Hoegh AM, Eugen-Olsen J, Bukh J.

J Infect Dis. 2008 Dec 15;198(12):1756-65. doi: 10.1086/593021.

19.

Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains.

Li YP, Ramirez S, Gottwein JM, Scheel TK, Mikkelsen L, Purcell RH, Bukh J.

Proc Natl Acad Sci U S A. 2012 May 1;109(18):E1101-10. doi: 10.1073/pnas.1203829109. Epub 2012 Mar 30.

20.

Analysis of functional differences between hepatitis C virus NS5A of genotypes 1-7 in infectious cell culture systems.

Scheel TK, Prentoe J, Carlsen TH, Mikkelsen LS, Gottwein JM, Bukh J.

PLoS Pathog. 2012;8(5):e1002696. doi: 10.1371/journal.ppat.1002696. Epub 2012 May 24.

Items per page

Supplemental Content

Write to the Help Desk